

13 Sep 2021 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Scrip's Five Must-Know Things: US industry warns over pricing; a setback for another gene therapy; a Phase II disappointment for Novartis; Actemra shortages cause CAR-T worries; and Sweden's Sobi set to go private.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 10 September 2021, including: US industry warns over pricing; a setback for another gene therapy; a Phase II blow for Novartis's transplant drug; Actemra shortages cause CAR-T challenges; and Sweden's Sobi set to go private.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Pharma On Its Back Foot As US Drug Price Reform Advances](#)" - Scrip, 8 Sep, 2021.)

(Also see "[BioMarin Trial Halt Raises Another Safety Flag On AAV Gene Therapy](#)" - Scrip, 6 Sep, 2021.)

(Also see "[Novartis's Big Hopes For Transplant Drug Blown Apart](#)" - Scrip, 3 Sep, 2021.)

(Also see "[COVID-19-Induced Actemra Shortage Causes Headaches For CAR-T Centers](#)" - Scrip, 6 Sep, 2021.)

(Also see "[Sobi To Go Private In \\$8.1bn Buyout That Appreciates Growth Strategy](#)" - Scrip, 2 Sep,

2021.)

[Click here to explore this interactive content online](#) 